Surgery remans an option for advanced lung cancer

Jul 27, 2009

In recent years, oncologists have debated whether patients with a certain type of advanced lung cancer would benefit from surgery.

Now a major study published in the journal The Lancet has found that surgery after standard and radiation can be an option for . Surgery significantly prolongs survival without progression of the , but does not dramatically improve overall survival compared to a control group treated with conventional chemotherapy and radiation alone.

The patients who did appear to have a major benefit from surgery were those in whom a section of the lung (lobe) was removed, rather than the entire lung, lead author Dr. Kathy Albain and colleagues reported. Albain is a lung and breast cancer specialist at Loyola University Health System's Cardinal Bernardin Cancer Center.

"This the first study conducted in this group of patients where the only difference in the two groups of patients was the use of surgery," Albain said.

In an accompanying editorial, German researcher Dr. Wilfried Eberhardt and colleagues wrote that as a result of the new study, "We now have clear arguments in favor of surgery in well-selected patient subsets."

The study included patients with non-small cell cancer, which accounts for about 80 percent of all lung cancers. Patients had stage 3 cancer, in which the cancer had spread to lymph nodes in the center of the chest. This type of stage 3 cancer accounts for about 30 percent of all non-small cell lung cancer cases. Patients were treated at multiple academic and community hospitals in the United States and Canada.

One group of 202 patients was randomly assigned to receive surgery plus chemotherapy and radiation, while a second group of 194 patients received just chemotherapy and radiation.

Median overall survival was similar between the two groups: 23.6 months in the surgery group and 22.2 months in the non-surgery group. After five years, 37 patients in the surgical group and 24 patients in the non-surgery group were still alive. The median length of time it took before the began to progress again after treatment was 12.8 months in the group and 10.5 months in the non-surgery group.

"Another important finding of our study is that both groups of patients lived longer than previously reporter for this stage of the disease," Albain said. "This highlights the importance of multidisciplinary evaluation and treatment -- which all patients deserve."

Source: Loyola University

Explore further: New cancer vaccine approach directly targets dendritic cells

add to favorites email to friend print save as pdf

Related Stories

If metastasectomy should be performed before other treatments

Oct 31, 2008

Primary HCC is a major cancer related to HBV viral infection in Asian countries, including Japan. Recently, the primary liver cancers are successfully treated by surgical resection including liver transplantation and non-surgical ...

High-dose radiation improves lung cancer survival

Apr 08, 2009

Higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

Recommended for you

Physicians target the genes of lung, colon cancers

6 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
not rated yet Jul 28, 2009
The options should include "cyroablation"!

More news stories

How kids' brain structures grow as memory develops

Our ability to store memories improves during childhood, associated with structural changes in the hippocampus and its connections with prefrontal and parietal cortices. New research from UC Davis is exploring ...

Gate for bacterial toxins found

Prof. Dr. Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of Experimental and Clinical Pharmacology and Toxicology of the University of Freiburg have discovered the receptor responsible ...

Adventurous bacteria

To reproduce or to conquer the world? Surprisingly, bacteria also face this problem. Theoretical biophysicists at Ludwig-Maximilians-Universitaet (LMU) in Munich have now shown how these organisms should ...